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Background
• 50.7 million Medicare beneficiaries
o 43.1 (85%) are 65+ years of age (seniors)
• 50% of beneficiaries have annual incomes <$22,0001
• % of seniors with incomes <100% of Supplemental 
Poverty Threshold2
o National Average = 15%
o California = 20% (highest in the country)
• 13 (41%) of 32 million beneficiaries with a Part D plan 
receive/qualify for the Low-Income Subsidy
1JAMA. 2012;308(20):2072. doi:10.1001/jama.2012.53860. 
2Current Population Survey 2009-2011 Annual Social & Economic Supplement 
Methods
• Twelve outreach events were held in 6 cities across
Northern/Central California during the fall of 2012
• Student pharmacists assisted beneficiaries during
individualized counseling sessions
o Cost minimization strategies
• Part D Plan Optimization
• Low-Income Subsidy
• Pharmaceutical Assistance Programs
• Therapeutic Interchange
• Potential out-of-pocket (OOP) cost reduction was
analyzed
• Demographic and Interventional data were collected
Demographic and Clinical Characteristics n (%) 
Sex, No. (%); n=589
Female 368 (61.4)
Male 221 (36.9)
Age, No. (%); n=573
<65 34 (5.9)
65-74 255 (44.5)
75-84 180 (31.4)
85+ 104 (18.2)
Mean + SD 75.5 + 9.0
Race, No. (%); n=586
White/Caucasian 368 (61.3)
Non-White/Non-Caucasian 219 (36.6)
Hispanic/Latino, No. (%); n=581
No 526 (90.5)
Yes 55 (9.5)
Preferred Language, No. (%); n=583
English 423 (72.6)
Non-English 160 (27.4)
Highest Level of Education Completed, No. (%); n=585
8th Grade or Less 56 (9.6)
Some High School (9th-12th grade) 47 (8.0)
High School Diploma or Equivalent 94 (16.1)
Some College or Associate Degree 144 (24.6)
Bachelor’s Degree or Higher 236 (40.3)
Prescription Drug Coverage Type, No. (%); n=599
Medicare Part D Stand-Alone Prescription 
Drug Plan(PDP)
426 (71.1)
Medicare Advantage Prescription Drug Plan
(MA-PDP)
86 (14.4)
Creditable Coverage 49 (8.2)
No Coverage 38 (6.3)
Prescription Drug Subsidy Status, No. (%); n=502
No Subsidy 311 (62.0)
Medicaid or Low-Income Subsidy  191 (38.0)
Prescriptions, No. (%); n=569
0 28 (4.9)
1-2 100 (17.6)
3-4 142 (24.9)
5-6 123 (21.6)
>6 176 (30.9)
Mean + SD 5.2 + 3.4
Prescription Drug Coverage Type,
No. (%); n=599 n (%)
Medicare Part D Stand-Alone 
Prescription Drug Plan (PDP)
426 (71.1)
Medicare Advantage Prescription Drug 
Plan (MA-PDP)
86 (14.4)
Creditable Coverage 49 (8.2)
No Coverage 38 (6.3)
Prescription Drug Subsidy Status, 
No. (%); n=502 n (%)
No Subsidy 311 (62.0)
Medicaid or Low-Income Subsidy  191 (38.0)
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Cost Minimization Strategies
Therapeutic Interchange
• Therapeutic Interchange- a medication that is chemically 
different, but therapeutically similar to another medication
o Potential for significant cost savings through therapeutic 
interchange.
• Based on information available on the Medicare website 
and the knowledge of assisting student pharmacists (under 
supervision of licensed pharmacists)
• OOP cost savings = Part D plan cost pre- and post-
therapeutic interchange
Therapeutic Interchange
n=7Mean Interventional  
Savings ($) + SD
$1,299 + $899 $9,093
Total Interventional 
Savings ($)
Low-Income Subsidy (LIS)
• LIS eligibility was determined by asking the beneficiary
about their income and assets.
o OOP cost savings = The difference in Part D Plan Costs as a
function of subsidy.
• This was determined through the Medicare website
Low-Income Subsidy
n=16
Therapeutic Interchange
n=7Mean Interventional  
Savings ($) + SD
P: $628 + $727
F: $823+ $895
$1,299 + $899
P: $11,936
F: $15,629
$9,093
Total Interventional 
Savings ($)
Pharmaceutical Assistance Programs 
(PAPs)
• Drug-specific PAPs were identified when the
beneficiary indicated have difficulty paying for certain
brand-name medications.
o OOP cost savings = Difference in cost for the drug(s)
in question under the PAP program as compared to
the current medication cost.
PAPs
Brand
Pharmaceutical 
Assistance Programs 
n=28
Low-Income Subsidy
n=16
Therapeutic Interchange
n=7Mean Interventional  
Savings ($) + SD
$1,274 + $1,301
P: $628 + $727
F: $823+ $895
$1,299 + $899
$35,808
P: $11,936
F: $15,629
$9,093
Total Interventional 
Savings ($)
PAPs
Brand
Part D Plan Optimization
• Part D plan optimization was performed via the Medicare
website (www.medicare.gov)
• OOP cost savings =
o [EAC($) of Current Plan in 2013 – EAC($) of Least Expensive
PDP in the 2013] where EAC = Estimated Annual Cost
Part D Plan 
Optimization
n=535
Pharmaceutical 
Assistance Programs 
n=28
Low-Income Subsidy
n=16
Therapeutic Interchange
n=7Mean Interventional  
Savings ($) + SD
$1,334 + $3,125
$1,274 + $1,301
P: $628 + $727
F: $823+ $895
$1,299 + $899
$713,502
$35,808
P: $11,936
F: $15,629
$9,093
Total Interventional 
Savings ($)
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Optimization
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n=16
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F: $15,629
$9,093
Total Interventional 
Savings ($)
Annual
Savings ($)
$0
n = 45
(23.6%)
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$0
$1-$99
$100-$399
$400-$999n = 4
(2.1%)
n = 81
(27.6%)
n = 14
(7.3%)
n = 45
(23.6%)
Annual
Savings ($)
Part D Plan 
Optimization
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Pharmaceutical 
Assistance Programs 
n=28
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n=16
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Savings ($) + SD
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n = 24
(8.2%)
n = 10
(3.4%)
n = 42
(14.3%)
$0
$1-$99
$100-$399
$400-$999
$1000-$1999
$2000-$2999
$3000+
n = 4
(2.1%)
n = 15
(7.9%)
n = 10
(5.2%)
n = 20
(10.5%)
n = 81
(27.6%)
n = 14
(7.3%)
Annual
Savings ($)
n = 45
(23.6%)
Conclusion
• OOP Savings from Cost-Minimization Strategies
oAggregate: ~$770,000
oAverage: ~$1,440/beneficiary
• Targeted assistance can significantly lower
beneficiary OOP costs.
• The majority (~80%) of beneficiaries, regardless
of subsidy-status, can save money by annually
re-evaluating Part D plan offerings.
Conclusion
• Advocates can potentially help lower beneficiary
OOP costs through assistance with the LIS and PAP
applications.
• (Student) pharmacists can help lower beneficiary
OOP costs by making recommendations for
cheaper therapeutic alternatives without
sacrificing the drug’s intended effects.
• Cost-minimization strategies can potentially lower
OOP costs, decrease cost-related medication
non-adherence and improve quality-of-life
